Neurophet gears for 2024 IPO after $15M Series C raise and more digital health fundings

0
31



Neurophet scores $15M in Sequence C funding, proclaims 2024 IPO

South Korean firm Neurophet, a supplier of mind picture evaluation software program, has raised 20 billion gained ($15 million) in a Sequence C funding spherical participated by institutional traders, resembling KB Securities, Mirae Asset Securities, and IBK Industrial Financial institution of Korea.

This brings its complete investments since its founding in 2016 to 50 billion gained ($39 million).

Neurophet has developed software program that may routinely analyse PET and MRI scans to detect biomarkers of Alzheimer’s illness, together with amyloid beta protein and tau protein. The Neurophet SCALE PET also can monitor amyloid-related imaging abnormalities or ARIA, noticed in sufferers present process anti–amyloid beta immunotherapies. 

Together with the anticipation of extra anti-amyloid beta immunotherapies coming to the market, Neurophet appears to be like to introduce a complete Alzheimer’s illness prognosis help software program, which incorporates ARIA monitoring, subsequent yr. 

In the meantime, Neurophet can be making ready for a public itemizing on the Korea Change’s small and medium ventures board KOSDAQ subsequent yr.


H2U secures funding, partnership in South Korea

Taiwan-based supplier of company digital well being options H2U has obtained an undisclosed strategic funding from Seoul Scientific Laboratories (SCL) Group by means of its affiliate firm, KOSDAQ-listed medical system agency InnoTherapy.

The deal will enable H2U to introduce its company and private well being administration options to the Korean market, beginning with adoption throughout SCL Group’s well being examination amenities in about 4,500 clinics nationwide. H2U, in flip, will help the SCL Group, by means of one other affiliate firm, AhealthZ, to ship its medical testing expertise and different merchandise in Taiwan.


SURGLASSES will get $6.5M pre-Sequence A funding

One other Taiwanese firm, SURGLASSES, has obtained recent funding price $6.5 million in a current elevate. The oversubscribed pre-Sequence A funding spherical was led by Taiwania Capital and took part by Built-in Capital, 500 STARTUPS, Knowledge Capital, and Sustainable Impression Capital. 

The proceeds will go to accelerating the R&D and promotion of its augmented reality-based surgical navigation system, the Caduceus S. The expertise, which is designed for complicated spinal surgical procedures, was recently cleared by the US FDA


InMed.ai secures 510(ok) for mind geometry analytics software program 

In-Med Prognostics (InMed.ai) has lately obtained a 510(ok) clearance from the US FDA for its volumetric mind evaluation software program. 

The NeuroShield calculates mind volumes from 3D MR scans to help the remedy of neurodegenerative illnesses. It’s mentioned to be the primary software program of its type to supply adjustable reference ranges for age, gender, and ethnicity.

LEAVE A REPLY

Please enter your comment!
Please enter your name here